Edward R Conner1, Sarbjit S Saini
1Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA.
Immunoglobulin E (IgE) interactions with its receptors are key in allergic diseases. Therapies targeting IgE receptors Fc epsilonRI and Fc epsilonRII (CD23) are advancing treatment options.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: